1.王素霞，邹万忠，王海燕.局灶节段性肾小球硬化症的病理诊断及分型.中华肾脏病杂志，2005，21（1）：55-58.

2.邹万忠，主编.肾活检病理学.北京：北京大学医学出版社，2006：61-67.

3.潘碧霞，姜宗培，常洁，等.263例成人原发性局灶节段性肾小球硬化性肾小球肾炎临床病理分析.中华肾脏病杂志，2007，23（1）：13-17.

4. Appel GB，Pollak MR，D’Agati VD.Focal Segmental Glomerulosclerosis：Genetic and Spontaneous Causes//Feehally J，Floege J，Johnson RJ，et al.Comprehensive Clinical Nephrology.3rd ed.Philadephia：Elsevier，2007：217-230.

5. Reidy K，Kaskel FJ. Pathophysiology of focal segmental glomerulosclerosis.Pediatr Nephrol，2007，22：350-354.

6. Hogg R，Middleton J，Vehaskari VM.Focal segmental glomerulosclerosis epidemiology aspects in children and adults.Pediatr Nephrol，2007，22：183-186.

7. Kopp JB，Smith MW，Nelson GW，et al.MYH9 is a majoreffect risk gene for focal segmental glomerulosclerosis.Nat Genet，2008，40（10）：1175-1184.

8. Genovese G，Tonna SJ，Knob AU，et al.A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9.Kidney Int，2010，78（7）：698-704.

9. Genovese G，Friedman DJ，Ross MD，et al.Association of trypanolytic ApoL1 variants with kidney disease in African Americans.Science，2010，329（5993）：841-815.

10. Stephen M.Korbet.Treatment of Primary FSGS in adults.J Am Soc Nephrol，2012，23（11）：1769-1776.

11. Xie J，Chen N.Primary glomerulonephritis in mainland-China：an overview.Contrib Nephrol，2013，181：1-11.

12. D’Agati VD，Kaskel FJ，Falk RJ.Focal segmental glomerulosclerosis.N Engl J Med，2011，365（25）：2398-2411.

13. Gbadegesin R，Lavin P，Foreman J，et al. Pathogenesis and therapy of focal segmental glomerulosclerosis：an update.Pediatr Nephrol，2011，26（7）：1001-1015.

14. Winkler CA，Nelson G，Oleksyk TK，et al.Genetics of focal segmental glomerulosclerosis and human immunodeficiency virus-associated collapsing glomerulopathy：the role of MYH9 genetic variation.Semin Nephrol，2010，30（2）：111-125.

15. Gbadegesin R，Lavin P，Janssens L，et al.A new locus for familial FSGS on chromosome 2p. J Am Soc Nephrol，2010，21（8）：1390-1397.

16. Ponticelli，C，Glassock，RJ.Post-transplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol，2010，5（12）：2363-2372.

17. Wei C，El Hindi S，Li J，et al.Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med，2011，17：952-961.

18. Gebeshuber CA，Kornauth C，Dong L，et al.Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1.Nat Med，2013，19（4）：481-487.

19. Strassheim D，Renner B，Panzer S，et al.IgM Contributes to Glomerular Injury in FSGS.J Am Soc Nephrol，2013，24（3）：393-406.

20. Kidney Disease：Improving Global Outcomes（KDIGO）Glomerulonephritis Work Group.KDIGO Clinical Practice Guidline for Glomerulonephritis.Kidney Int，2012，Suppl 2：139-274.

21. Troyanov S，Wall CA，Miller JA，et al.Focal and segmental glomerulosclerosis：Definition and relevance of a partial remission.J Am Soc Nephrol，2005，16：1061-1068.

22. Stirling CM，Mathieson P，Boulton-Jones，et al.Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units.QJM，2005，98：443-449.

23. Chun MJ，Korbet SM，Schwartz MM，et al.Focal segmental glomerulosclerosis in nephritic adults：presentation，prognosis，and response to therapy of the histologic variant.J Am Soc Nephrol，2004，8：2169-2177.

24. Meyrier A.An update on the treatment options for focal segmental glomerulosclerosis.Expert Opin Phamacother，2009，10：615-628.

25. Cattran DC，Appel GB，Hebert LA，et al.A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.Kidney Int，1999，56（6）：2220-2226.

26. Gipson DS，Trachtman H，Kaskel FJ，et al.Clinical trial of focal segmental glomerulosclerosis in children and young adults.Kidney Int，2011，80（8）：868-678.

27. Plank C，Kalb V，Hinkes B，et al.Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie.Pediatr Nephrol，2008，23（9）：1483-1493.

28. Ren H，Shen P，Li X，et al.Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis：A randomized controlled trial.Am J Nephrol，2013，37：84-90.

29. Fan L，Liu Q，Liao Y，et al.Tacrolimus is an alternative therapy option for the treatment of adult steroid-resistant nephrotic syndrome：a prospective，multicenter clinical trial.Int Urol Nephrol，2013，45（2）：459-468.

30. Lau EW，Ma PH，Wu X，et al.Mycophenolate mofetil for primary focal segmental glomerulosclerosis：systemic review.Ren Fail，2013，35（6）：914-929.

31. Joy MS，Gipson DS，Powell L，et al.Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis（FSGS）：Ⅱ.Report of the FONT（Novel Therapies for Resistant FSGS）study group.Am J Kidney Dis，2010，55（1）：50-60.

32. Ponticelli C，Graziani G.Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults.Expert Rev Clin Immunol，2013，9（3）：251-261.

33. Kronbichler A，Mayer G.Nephrotic syndrome；is rituximab the light at the end of the tunnel in the treatment of adult steroid-dependent minimal change disease and focal segmental glomerulosclerosis？J Nephropathol，2014，3（1）：1-3.